By Peter Loftus
Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad.
Roche will invest $50 billion over five years, including in a new factory to make glucose-monitoring devices and a new plant for weight-loss drugs. The Swiss drugmaker said the investments will create 12,000 construction and other jobs.
Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm's plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.
Chief Executive Leonard Schleifer said the deal would bolster the supply of Regeneron's medicines "while generating economic growth and high-paying jobs for America itself." Regeneron also makes medicines in New York State and Limerick, Ireland.
In addition to a new global baseline tariff, the Trump administration opened an investigation that could lead to tariffs on imported medicines, potentially in May. Drugmakers including Eli Lilly and Johnson & Johnson have trumpeted new plans in recent weeks to grow their U.S. manufacturing footprint.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 22, 2025 06:51 ET (10:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。